These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 8815575

  • 1. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
    Zöller B, Holm J, Svensson P, Dahlbäck B.
    Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
    [Abstract] [Full Text] [Related]

  • 2. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B.
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [Abstract] [Full Text] [Related]

  • 3. Thrombophilia as a multigenic disease.
    Zöller B, García de Frutos P, Hillarp A, Dahlbäck B.
    Haematologica; 1999 Jan; 84(1):59-70. PubMed ID: 10091393
    [Abstract] [Full Text] [Related]

  • 4. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V, Leone G.
    Haematologica; 1995 Jan; 80(4):344-56. PubMed ID: 7590506
    [Abstract] [Full Text] [Related]

  • 5. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B.
    Semin Thromb Hemost; 1999 Jan; 25(3):273-89. PubMed ID: 10443959
    [Abstract] [Full Text] [Related]

  • 6. Heightened thrombin generation in individuals with resistance to activated protein C.
    Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM.
    Thromb Haemost; 1996 May; 75(5):703-5. PubMed ID: 8725708
    [Abstract] [Full Text] [Related]

  • 7. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
    De Lucia D, Papa ML, Ammendola F, Pezzella S, Del Giudice V, Marotta R, Renis V, Di Mauro C, Maisto G, Masi S, Nina P, Franco A, Schisano G.
    J Neurosurg Sci; 1999 Mar; 43(1):45-50; discussion 50-1. PubMed ID: 10494665
    [Abstract] [Full Text] [Related]

  • 8. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
    Zöller B, He X, Dahlbäck B.
    Thromb Haemost; 1995 May; 73(5):743-5. PubMed ID: 7482396
    [Abstract] [Full Text] [Related]

  • 9. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
    De Lucia D, De Francesco F, Marotta R, Maisto G, Meo D, Sessa M, Misso M, Galante M, Russo T, Pignalosa O, Napolitano M, Papa ML, Niglio A, Di Micco P.
    Exp Oncol; 2005 Jun; 27(2):159-61. PubMed ID: 15995637
    [Abstract] [Full Text] [Related]

  • 10. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B.
    J Intern Med Suppl; 1997 Jun; 740():1-8. PubMed ID: 9350175
    [Abstract] [Full Text] [Related]

  • 11. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families?
    Koeleman BP, van Rumpt D, Hamulyák K, Reitsma PH, Bertina RM.
    Thromb Haemost; 1995 Aug; 74(2):580-3. PubMed ID: 8584987
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Activated protein C resistance: molecular mechanisms.
    Griffin JH, Heeb MJ, Kojima Y, Fernández JA, Kojima K, Hackeng TM, Greengard JS.
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [Abstract] [Full Text] [Related]

  • 14. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B.
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [Abstract] [Full Text] [Related]

  • 15. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J, Thomassen MC, Rimmer J, Hamulyak K, van der Meer J, Tans G, Preston FE, Rosing J.
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [Abstract] [Full Text] [Related]

  • 16. Ischaemic stroke in infancy and childhood: role of the Arg506 to Gln mutation in the factor V gene.
    Nowak-Göttl U, Sträter R, Dübbers A, Oleszuk-Raschke K, Vielhaber H.
    Blood Coagul Fibrinolysis; 1996 Oct; 7(7):684-8. PubMed ID: 8958390
    [Abstract] [Full Text] [Related]

  • 17. [Resistance to activated protein C. The most common cause of familial thrombophilia].
    Larsen TB, Ravn HB, Lassen JF, Lund ED, Brandslund I.
    Ugeskr Laeger; 1996 Nov 11; 158(46):6584-8. PubMed ID: 8966822
    [Abstract] [Full Text] [Related]

  • 18. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
    Lowe GD, Rumley A, Woodward M, Reid E, Rumley J.
    Thromb Haemost; 1999 Jun 11; 81(6):918-24. PubMed ID: 10404768
    [Abstract] [Full Text] [Related]

  • 19. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
    Zöller B, Svensson PJ, He X, Dahlbäck B.
    J Clin Invest; 1994 Dec 11; 94(6):2521-4. PubMed ID: 7989612
    [Abstract] [Full Text] [Related]

  • 20. Factor V and protein S as cofactors to activated protein C.
    Dahlbäck B.
    Haematologica; 1997 Dec 11; 82(1):91-5. PubMed ID: 9107093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.